250 related articles for article (PubMed ID: 18090504)
1. Long-term efficacy of pregabalin in generalized anxiety disorder.
Feltner D; Wittchen HU; Kavoussi R; Brock J; Baldinetti F; Pande AC
Int Clin Psychopharmacol; 2008 Jan; 23(1):18-28. PubMed ID: 18090504
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability.
Montgomery S; Emir B; Haswell H; Prieto R
Curr Med Res Opin; 2013 Oct; 29(10):1223-30. PubMed ID: 23808960
[TBL] [Abstract][Full Text] [Related]
3. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.
Feltner DE; Liu-Dumaw M; Schweizer E; Bielski R
Int Clin Psychopharmacol; 2011 Jul; 26(4):213-20. PubMed ID: 21368587
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.
Feltner DE; Crockatt JG; Dubovsky SJ; Cohn CK; Shrivastava RK; Targum SD; Liu-Dumaw M; Carter CM; Pande AC
J Clin Psychopharmacol; 2003 Jun; 23(3):240-9. PubMed ID: 12826986
[TBL] [Abstract][Full Text] [Related]
6. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial.
Hadley SJ; Mandel FS; Schweizer E
J Psychopharmacol; 2012 Apr; 26(4):461-70. PubMed ID: 21693549
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study.
Greist JH; Liu-Dumaw M; Schweizer E; Feltner D
Int Clin Psychopharmacol; 2011 Sep; 26(5):243-51. PubMed ID: 21734588
[TBL] [Abstract][Full Text] [Related]
8. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.
Kasper S; Brasser M; Schweizer E; Lyndon G; Prieto R
Eur Neuropsychopharmacol; 2014 Jan; 24(1):125-32. PubMed ID: 24290532
[TBL] [Abstract][Full Text] [Related]
9. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.
Bandelow B; Wedekind D; Leon T
Expert Rev Neurother; 2007 Jul; 7(7):769-81. PubMed ID: 17610384
[TBL] [Abstract][Full Text] [Related]
10. Pregabalin for the treatment of generalized anxiety disorder.
Wensel TM; Powe KW; Cates ME
Ann Pharmacother; 2012 Mar; 46(3):424-9. PubMed ID: 22395254
[TBL] [Abstract][Full Text] [Related]
11. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Baldwin DS; Schweizer E; Xu Y; Lyndon G
Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
[TBL] [Abstract][Full Text] [Related]
12. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.
Baldwin DS; Loft H; Florea I
Int Clin Psychopharmacol; 2012 Jul; 27(4):197-207. PubMed ID: 22475889
[TBL] [Abstract][Full Text] [Related]
13. Pregabalin in generalized anxiety disorder: a placebo-controlled trial.
Pande AC; Crockatt JG; Feltner DE; Janney CA; Smith WT; Weisler R; Londborg PD; Bielski RJ; Zimbroff DL; Davidson JR; Liu-Dumaw M
Am J Psychiatry; 2003 Mar; 160(3):533-40. PubMed ID: 12611835
[TBL] [Abstract][Full Text] [Related]
14. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
15. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder.
Kasper S; Iglesias-García C; Schweizer E; Wilson J; DuBrava S; Prieto R; Pitman VW; Knapp L
Int J Neuropsychopharmacol; 2014 May; 17(5):685-95. PubMed ID: 24351233
[TBL] [Abstract][Full Text] [Related]
16. Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model.
Nutt D; Mandel F; Baldinetti F
J Psychopharmacol; 2009 Nov; 23(8):867-73. PubMed ID: 18635690
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
Montgomery SA; Tobias K; Zornberg GL; Kasper S; Pande AC
J Clin Psychiatry; 2006 May; 67(5):771-82. PubMed ID: 16841627
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
Merideth C; Cutler AJ; She F; Eriksson H
Int Clin Psychopharmacol; 2012 Jan; 27(1):40-54. PubMed ID: 22045039
[TBL] [Abstract][Full Text] [Related]
20. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
